{"filing":{"accession_number":"0001178913-26-003551","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"zk2635714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003551/zk2635714.htm"},"events":[{"id":19106,"run_id":17194,"accession_number":"0001178913-26-003551","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Shareholders voted at a reconvened meeting on July 20, 2026, approving two proposals: warrant exercisability (93.3% in favor) and an increase in authorized share capital by 10 million shares (89.8% in favor). Both proposals passed by majority vote, materially affecting the company's capital structure and warrant obligations.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":[{"id":18103,"accession_number":"0001178913-26-003551","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a shareholder-approved amendment to the Company's memorandum of association increasing authorized share capital. While the amendment itself is a governance matter requiring Item 5.03 disclosure, the increase in authorized shares is a routine administrative action that does not materially affect the registrant's financial condition, operations, or investor risk profile absent actual issuance of those shares. The filing cross-references Item 5.07 (shareholder vote results), confirming the procedural nature of the disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:09:07.691429+00:00","company_name":"","ticker":null,"filing_date":""},{"id":18104,"accession_number":"0001178913-26-003551","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a shareholder vote at a reconvened meeting on July 20, 2026. Shareholders voted on two proposals: approval of warrant exercisability (93.3% in favor) and an increase in authorized share capital by 10 million shares (89.8% in favor). Both proposals were approved by majority vote. These are material governance matters affecting the company's capital structure and warrant obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:09:07.691429+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18103,"accession_number":"0001178913-26-003551","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a shareholder-approved amendment to the Company's memorandum of association increasing authorized share capital. While the amendment itself is a governance matter requiring Item 5.03 disclosure, the increase in authorized shares is a routine administrative action that does not materially affect the registrant's financial condition, operations, or investor risk profile absent actual issuance of those shares. The filing cross-references Item 5.07 (shareholder vote results), confirming the procedural nature of the disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:09:07.691429+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-07-21"},{"id":18104,"accession_number":"0001178913-26-003551","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a shareholder vote at a reconvened meeting on July 20, 2026. Shareholders voted on two proposals: approval of warrant exercisability (93.3% in favor) and an increase in authorized share capital by 10 million shares (89.8% in favor). Both proposals were approved by majority vote. These are material governance matters affecting the company's capital structure and warrant obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:09:07.691429+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-07-21"}]}